Replies to post #132793 on Biotech Values

[biomaven0]

There is no valid reason to preserve alpha in an exploratory Phase IIa dose-finding trial.

Well unless they believe the 100% cure was one of their drug arms, in which case they may secretly harbor hopes of showing superiority over daptomycin in this trial.

Peter